

References

1. Doulatov S, Notta F, Laurenti E, Dick JE. Hematopoiesis: a human perspective. *Cell Stem Cell*. 2012;10(2):120-136. 10.1016/j.stem.2012.01.006.
2. Bradley TR, Metcalf D. The growth of mouse bone marrow cells in vitro. *AustJExpBiolMedSci*. 1966;44:287-293.
3. Gregory CJ, Eaves AC. Human marrow cells capable of erythropoietic differentiation in vitro: definition of three erythroid colony responses. *Blood*. 1977;49:855.
4. Ema H, Suda T. Two anatomically distinct niches regulate stem cell activity. *Blood*. 2012;120(11):2174-2181. Prepublished on 2012/07/13 as DOI 10.1182/blood-2012-04-424507.
5. Krause DS, Scadden DT. Deconstructing the complexity of a microenvironmental niche. *Cell*. 2012;149(1):16-17. 10.1016/j.cell.2012.03.005.
6. de la Chapelle A, Traskelin A-L, Juvonen E. Truncated erythropoietin receptor causes dominantly inherited benign human erythrocytosis. *ProcNatlAcadSciUSA*. 1993;90:4495-4499.
7. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activation. *Science*. 1999 Feb 12;283(5404):987-990.
8. Franke K, Gassmann M, Wielockx B. Erythrocytosis: the HIF pathway in control. *Blood*. 2013;122(7):1122-1128. 10.1182/blood-2013-01-478065.
9. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. *Blood*. 2010;116(20):4045-4059. 10.1182/blood-2010-08-300541.
10. Gupta G, Choi MJ. Is it safe to use erythropoiesis-stimulating agents to treat anemia in chronic kidney disease patients with active malignancies? *Semin Dial*. 2011;24(4):379-381. 10.1111/j.1525-139X.2011.00929.x.
11. Bohlius J, Wilson J, Seidenfeld J, et al. Erythropoietin or darbepoetin for patients with cancer. *Cochrane Database Syst Rev*. 2006;3:CD003407.
12. Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. *Br J Cancer*. 2010;102(2):301-315. 10.1038/sj.bjc.6605498.
13. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med*. 1998;339(9):584-590. 10.1056/NEJM199808273390903.
14. Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *N Engl J Med*. 2009;361(21):2019-2032. 10.1056/NEJMoa0907845.

15. Weise M, Kurki P, Wolff-Holz E, Bielsky MC, Schneider CK. Biosimilars: the science of extrapolation. *Blood*. 2014;124(22):3191-6.
16. Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Oncol*. 2015 Jul 13. pii: JCO.2015.62.3488. [Epub ahead of print]
17. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. *J Clin Oncol*. 2007;25(21):3158-3167. 10.1200/JCO.2006.08.8823.
18. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. *J Clin Oncol*. 2001;19(10):2638-2646.
19. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. *J Clin Oncol*. 2005;23(6):1178-1184. 10.1200/JCO.2005.09.102.
20. Linch DC, Milligan DW, Winfield DA, et al. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: results of a randomized BNLI trial. *Br J Haematol*. 1997;99(4):933-938.
21. Berchanski A, Kalinkovich A, Ludin A, Lapidot T, Lapidot A. Insights into the mechanism of enhanced mobilization of hematopoietic progenitor cells and release of CXCL12 by a combination of AMD3100 and aminoglycoside-polyarginine conjugates. *FEBS J*. 2011;278(21):4150-4165. 10.1111/j.1742-4658.2011.08348.x.
22. Mohty M, Ho AD. In and out of the niche: perspectives in mobilization of hematopoietic stem cells. *Exp Hematol*. 2011;39(7):723-729. 10.1016/j.exphem.2011.05.004.
23. Cheng J, Schmitt M, Wuchter P, et al. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. *Transfusion*. 2014. 10.1111/trf.12813.
24. Rosenberg PS, Alter BP, Bolyard AA, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. *Blood*. 2006;107(12):4628-4635. 10.1182/blood-2005-11-4370.
25. Marsh JC, Ganser A, Stadler M. Hematopoietic growth factors in the treatment of acquired bone marrow failure states. *Semin Hematol*. 2007;44(3):138-147. 10.1053/j.seminhematol.2007.04.010.
26. Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. *J Clin Oncol*. 2010;28(17):2914-2924. 10.1200/JCO.2009.25.8723.

27. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. *Blood*. 2011;118(1):28-36. 10.1182/blood-2010-10-313908.
28. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. *Blood*. 2013;121(3):537-545. 10.1182/blood-2012-04-425512.
29. Desmond R, Townsley DM, Dumitriu B, et al. Eltrombopag restores trilineage hematopoiesis in refractory severe aplastic anemia that can be sustained on discontinuation of drug. *Blood*. 2014;123(12):1818-1825. 10.1182/blood-2013-10-534743.